Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
Mitka
Mike
M
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000473:pathology; D008078:Cholesterol, LDL / Q000187:drug effects*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D009525:Niacin / Q000008:administration & dosage; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D012307:Risk Factors; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome; D014463:Ultrasonography; D014481:United States; D014486:United States Food and Drug Administration
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D019821:Simvastatin; D000069438:Ezetimibe